Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZymoGenetics Will Ship Topical Hemostat Recothrom In Two Weeks

This article was originally published in The Pink Sheet Daily

Executive Summary

Company will price the recombinant, plasma-free thrombin at a 20 percent premium over competitor King's bovine-derived Thrombin JMI.
Advertisement

Related Content

ZymoGenetics Claims Competitor's Product Poses Serious Patient Safety Issue
Atacicept R&D Cost Gone, ZymoGenetics Makes Plans
Merck-Serono Takes Over Atacicept Development In Partnership Restructuring
J&J/Omrix’s Evicel Wins CHMP Recommendation
FDA Challenges ZymoGenetics' Safety Claims
ZymoGenetics' Biotech Disconnect
Wyeth’s Xyntha Wins FDA Nod For Hemophilia A
Johnson & Johnson/Omrix Win General Surgery Hemostasis Approval For Evicel
Johnson & Johnson/Omrix Win General Surgery Hemostasis Approval For Evicel
FDA Extends ZymoGenetics’ rhThrombin Action Date To Jan. 17

Topics

Advertisement
UsernamePublicRestriction

Register

PS066745

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel